Jeffrey Magee
pediatric AML
Jeffrey Magee, PhD, MD
St. Louis, MO
United States
Washington University School of Medicine in St. Louis
Dr. Magee directs the pediatric leukemia and lymphoma program at Washington University School of Medicine and St. Louis Children’s Hospital. He received his M.D. and Ph.D. from Washington University and then completed a pediatrics residency and hematology/oncology fellowship at the University of Michigan. He conducted postdoctoral research with Dr. Sean Morrison (Howard Hughes Medical Institute) at the University of Michigan and UT-Southwestern. Dr. Magee’s work focuses on causes and treatments for childhood acute myeloid leukemia. He has published several papers in high impact journals investigating interactions between genes that regulate normal childhood blood development and mutations that cause leukemia, with the goal of understanding why childhood leukemias respond differently to treatment than adult leukemias. He is also investigating changes in blood forming stem cells that lead to leukemia when children receive chemotherapy for other tumors, such as lymphomas or solid tumors.
Program Name(s)
Career Development Program
Project Title
Michael Bern, MD, PhD
St. Louis, MO
United States
Washington University in St. Louis
Dr. Bern is a post-doctoral fellow in Dr. Timothy Ley’s lab at Washington University School of Medicine and a clinical fellow in the Hematology and Oncology program. He earned his bachelor’s degree in Physics from Duke University. Following undergraduate, he completed M.D./Ph.D. training at Washington University School of Medicine, where he earned his Ph.D. in Immunology, studying mechanisms regulating natural killer cell activation, in the laboratory of Dr. Wayne Yokoyama. He then joined the Physician Scientist Training Program at Washington University School of Medicine for Internal Medicine residency and Heme/Onc fellowship. His current research is focused on understanding mechanisms of chemotherapy resistance in Primary-Refractory Acute Myeloid Leukemia. His long-term goal is to identify novel therapeutic strategies for this population of patients with extremely poor outcomes and few treatment options.
Program Name(s)
Career Development Program
Project Title
Michael Girardi, MD
New Haven, CT
United States
Yale University
The first-generation in his family to attend college, Dr. Girardi is the Evans Professor of Dermatology and Vice Chair of Faculty Development & Scientific Innovation at the Yale School of Medicine. The previous Co-Director of the Immunology and Immunotherapy Program for the Yale Cancer Center, Dr. Girardi has committed his career as a physician-scientist to the care of lymphoma patients and the discovery of new treatments. Dr. Girardi has led a highly collaborative research program funded by the National Cancer Institute for 20+ years investigating lymphoma and immunology, including major findings on the genetics, therapeutics development, and formulation of treatment guidelines through the U.S. Cutaneous Lymphoma Consortium and International Society of Cutaneous Lymphoma. Dr. Girardi also serve on the Leadership Council for Advancing Innovation in Dermatology and has been elected to the American Society for Clinical Investigation and the Association of American Physicians.
Program Name(s)
Translational Research Program
Project Title
Personalized Anti-TCRVbeta2 therapeutic antibody and ADC for T Cell Leukemias and Lymphomas
Andrew Lane
BPDCN
Andrew Lane, PhD, MD
Boston, MA
United States
Dana-Farber Cancer Institute
Dr. Lane’s laboratory and translational research focuses on the biology of high-risk blood cancers, including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and blastic plasmacytoid dendritic cell neoplasm (BPDCN). His goal is to identify new therapeutic targets and to understand treatment resistance. He is an associate professor of medicine at Harvard Medical School, a physician in the Leukemia Program, and a lab investigator in the Division of Hematologic Neoplasia in the Department of Medical Oncology at the Dana-Farber Cancer Institute. He is director of the BPDCN Center at Dana-Farber. He is also an associate member of the Broad Institute of Harvard and MIT. Dr. Lane received a bachelor’s degree in biomedical engineering from Vanderbilt University, and MD and PhD degrees from Washington University. He completed a residency in internal medicine at Brigham and Women’s Hospital and fellowships in hematology and medical oncology at the Dana-Farber Cancer Institute.
Program Name(s)
Career Development Program
Project Title
Margaret Shipp
lymphoma biology
Margaret Shipp, MD
Boston, MA
United States
Dana-Farber Cancer Institute
Margaret Shipp, MD, is Chief of the Division of Hematologic Neoplasia at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School. Her research focuses on the clinical and molecular heterogeneity of the large B-cell lymphomas (LBCLs) and Hodgkin lymphomas. Dr. Shipp has led efforts to define molecular signatures of LBCLs and Hodgkin lymphomas, identify biologically distinct subsets of these diseases, and characterize associated rational treatment targets including modulators of the host anti-tumor immune response.
Program Name(s)
Translational Research Program
Project Title
Analysis and Targeting of Tumor-Associated Monocytes/Macrophages that Inhibit PD-1 Blockade
Amit Verma
AML/MDS
Amit Verma, MBBS
Bronx, NY
United States
Albert Einstein College of Medicine
Dr Verma has been involved in study of blood cancers such as MDS and AML in the lab and in the clinic. His work has defined the critical role of various signaling pathways (p38 MAP kinase, TGF-beta, smad2/3, IRAK and others) activation in MDS and CMML and this work has directly led to the therapeutic targeting as these pathways in clinical trials in MDS/AML (Nat Cell Bio 2019, JCI 2018, Blood 2015, 2011, JCO 2020, NEJM 2020). The FDA approval of Luspatercept in MDS was also supported by his work in the lab. Dr Verma was on the team to first define stem cell alterations in MDS/AML (Nat Med, 2018; JCI 2014, Blood 2012). Dr Verma has conducted clinical studies in blood cancers (Nat Med, 2022, Cancer Cell 2021, Can Disc, 2020; JAMA Onc 2018) that have studied the effects of COVID-19 and environmental exposures (WTC 911 disaster) on outcomes and pathogenesis. He has also been actively engaged in early phase clinical trials that are investigating novel agents for MDS and AML.
Program Name(s)
CMML Initiative
Project Title
Thomas Witzig, MD
Rochester, MN
United States
Mayo Clinic
Coming soon.
Program Name(s)
IMPACT
Project Title
REACH: Recruitment Expansion through community Access to Clinical trials in Hematologic malignancies
.jpeg?crop=true&keep=n&w=336&h=336)
Hannah Maul-Newby, PhD
New Haven, CT
United States
Yale University
I received my BS in biochemistry from Gonzaga University and my PhD in Molecular, Cell and Developmental Biology under the guidance of Dr. Melissa Jurica at UC Santa Cruz. In the Jurica lab, I studied RNA splicing, the fundamental process of removing non-coding pieces of RNA from regions which code proteins. My dissertation focused on the characterization of an RNA helicase and its role in early spliceosome assembly. Early spliceosomal proteins are commonly mutated in human diseases such as blood cancers, but until recently, scientists did not have the tools to allow for dissection of the mechanisms involved. I chose to pursue my postdoctoral training in a blood cancer lab to dive deep into the role of splicing factor mutations in myelodysplastic syndromes and leukemia. I seek to apply my expertise in RNA processing biochemistry to blood cancers with the goal to contribute to better understanding and novel therapeutic approaches.
Program Name(s)
Career Development Program
Project Title
Revisiting splicing factor mutations in MDS/AML – delving deep and wide
Ravindra Majeti
preleukemia, AML
Ravindra Majeti, MD, PhD
Palo Alto, CA
United States
Board of Trustees of the Leland Stanford Junior University
Dr. Majeti is Professor of Medicine, Chief of the Division of Hematology, and Member of the Institute for Stem Cell Biology and Regenerative Medicine at the Stanford University School of Medicine. He is a board-certified hematologist. While at Stanford, he completed post-doctoral training in the laboratory of Irving Weissman, MD, where he investigated acute myeloid leukemia (AML) stem cells and therapeutic targeting with anti-CD47 antibodies. Dr. Majeti directs an active NIH-funded laboratory that focuses on the molecular characterization and therapeutic targeting of leukemia stem cells in human hematologic disorders, particularly AML, and has published over 100 peer-reviewed articles.
Program Name(s)
CMML Initiative
Project Title
Sahand Hormoz
MPN
Sahand Hormoz, PhD
Boston, MA
United States
Dana-Farber Cancer Institute
Dr. Hormoz is an Assistant Professor with the Department of Systems Biology at Harvard Medical School and Department of Data Science at the Dana-Farber Cancer Institute. He obtained his PhD in Applied Physics from Harvard University. His postdoctoral studies were conducted jointly as a theorist at the Kavli Institute of Theoretical Physics (UCSB), and as an experimentalist at Caltech. Hormoz lab’s mission is to control biological systems to understand life and cure disease such as cancer. His lab develops new technologies for recording and measuring the molecular states of individual cells and computational frameworks for interpreting the large data sets that these measurements generate. Dr. Hormoz’s research on blood cancers has focused on reconstructing the history of cancer in individual patients to understand when cancer first occurs and how cancer cells expand in each patient.
Program Name(s)
Discovery
Project Title
Martin Carroll, MD
Philadelphia, PA
United States
Perelman School of Medicine at the University of Pennsylvania
Dr. Carroll is a physician scientist who has been studying leukemia biology for 3 decades. Until recently Dr. Carroll saw patients with blood cancers at the Philadelphia Veterans Administration Hospital but is now focused solely on research to improve therapy for AML. He has performed that research at the Univeristy of Pennsylvania since 1998. Dr. Carroll has had a long term commitment to building tools to enhance the understanding of human AML. These tools have included development of a large tissue bank of patient samples. He has also lead the field in development and application of the study of AML in immunocompromised mice. His work in xenograft AML models lead to the characterization of chemotherapy resistance as not always being dependent on leukemic stem cells but on metabolic adaptations of the cells to chemotherapy. Dr. Carroll has been involved in development of previous novel therapies for AML and continues to focus on developing safer and more effective treatments.
Program Name(s)
Specialized Center of Research Program
Project Title
Daphne Friedman
Equity in Access
Daphne Friedman, MD
Durham, NC
United States
Durham VA Health Care System
Dr. Friedman is a hematologist-oncologist at the Durham VA Health Care System (DVAHCS) and National TeleOncology (NTO) Program, a Professor at the Duke University School of Medicine, and is the Deputy Director of the VA National Oncology Program. She is the DVAHCS site PI for the NCI and VA Interagency Group to Accelerate Trials Enrollment (NAVIGATE) program, which facilitates enrollment of Veterans with cancer into NCI-funded clinical trials. She is the lead for the Cancer Clinical Research Service (CCRS) in NTO, which offers clinical trial navigation to Veterans with cancer and runs decentralized cancer clinical trials across the VA network.
Program Name(s)
Equity in Access
Project Title
REACH: Researching & Enhancing Access to Clinical trials in Veterans with Hematologic cancers